High Perfomance in Quantification and Monitoring of Biomolecular Interactions

GenOptics SPRi-Plex, one of the SPRi instruments commercialized by the company.

GenOptics is a European laboratory instrumentation company focused on the development of high performance systems with advanced optical imaging (SPRi) to quantify and monitor biomolecular interactions. GenOptics systems have direct applications in the demanding fields of proteomics, drug screening and drug discovery. GenOptics currently markets two protein-array platforms: the SPRi-Plex^TM is designed to automate large scale screening operations, and SPRi-Lab+^TM is an open configuration for experiments.

Surface Plasmon Resonance imaging technology (SPRi) is used to monitor protein-protein interactions in real-time. A dedicated video camera records activity as it occurs on the surface of a biochip. All molecular interactions are monitored dynamically and information is transformed into quantitative data. Once processed, the images provide valuable information about the quantification, the affinity and the kinetics of the molecules.

Large (or small) series (up to 400) of label-free binding studies are performed in multiplex which means simultaneous measurement of all of the phenomena observed on a biochip surface throughout an entire reaction.

Main advantages

1. Label-free: no labelling is required

You save time and expense, while you prevent your precious biomolecules from possible conformational changes which may occur when labelling.

2. Real time: SPRi offers imagery in real time

In SPRi, the active surface of the glass prism (the SPRi-Biochip^TM) is illuminated at a defined wavelength. From start to finish, the entire run is filmed at a rate of 1 image per second by a highly sensitive CCD camera. The operator can observe the activity of circulating molecules as they associate and dissociate with their grafted targets. In addition, all kinetic curves are displayed on the monitor screen and recorded for future analysis.

3. Advanced optical capabilities 

Multiplex SPRi has advanced optical capabilities that make it possible to spot multiple targets on the same biochip at the same time.
In SPRi, you can immobilize from 1 to 400 molecules (probes) in any concentration and in any position on the biochip. The molecules may be related or from completely different families.

Turn-over 31/09/2005: 380 K€
Turn-over 31/09/2006 (preliminary): 745 K€

GenOptics and Nano2Life

CEO Philippe Kerourédan says: "Regarding the relationship between N2L and GenOptics, we can say that GenOpitcs has been involved with N2L from the beginning. Since then we participated and brought our contribution to the major events organized by N2l. From a GenOpitics perspective, N2L is an essential European network where scientists from academic/private institutions and rom different European countires can exchange in a cross feritlization process and carry out fruitful collaborations."